BLACKSTONE LIFE SCIENCES
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
BLACKSTONE LIFE SCIENCES
Status:
Active
Similar Organizations
BBH Capital Partners
The private-equity arm of New York
Oaktree Capital Management
Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Platform Ventures
Platform Ventures, a real estate private equity investment firm.
Rhone Capital
Rhone Capital is a private equity arm of Rhone Group.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-15 | Sanofi | Blackstone Life Sciences investment in Post-IPO Equity - Sanofi | 300 M EUR |
| 2021-08-10 | Harmony Biosciences | Blackstone Life Sciences investment in Post-IPO Equity - Harmony Biosciences | 30 M USD |
| 2020-11-19 | Imago BioSciences | Blackstone Life Sciences investment in Series C - Imago BioSciences | 80 M USD |
| 2020-10-06 | Talaris Therapeutics | Blackstone Life Sciences investment in Series B - Talaris Therapeutics | 115 M USD |
| 2020-07-28 | Praxis Precision Medicines | Blackstone Life Sciences investment in Series C - Praxis Precision Medicines | 110 M USD |
| 2020-07-01 | Annexon Biosciences | Blackstone Life Sciences investment in Series C - Annexon Biosciences | 100 M USD |
| 2020-06-15 | Medtronic | Blackstone Life Sciences investment in Post-IPO Equity - Medtronic | 337 M USD |
| 2020-06-11 | Reata Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Reata Pharmaceuticals | 350 M USD |
| 2020-04-13 | Alnylam Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Alnylam Pharmaceuticals | 250 M USD |
More informations about "Blackstone Life Sciences"
Blackstone Life Sciences - Crunchbase
Blackstone Life Sciences invests in early to late-stage biotechnology and healthcare companies, focusing on therapeutics. Their investment strategy is concentrated in the United States, particularly in Massachusetts, California, …See details»
Blackstone Life Sciences - Crunchbase
May 15, 2024 Blackstone Life Sciences is a private equity segment of The Blackstone Group.See details»
How Blackstone Bolted Past Rivals in Life Sciences
May 13, 2024 Blackstone’s business model is well suited for life sciences. Its $1 trillion of assets under management are spread over more than 230 portfolio companies and massive holdings in real estate ...See details»
Uniquity Bio | Innovation in Immunology & Inflammation
May 15, 2024 Uniquity Bio was built by a leadership team with decades of experience in immunology and inflammation and a successful track record advancing clinical programs …See details»
Medtronic Announces a $337 Million Product Investment from …
Jun 12, 2020 Investment with Blackstone Life Sciences Expected to Accelerate Medtronic Diabetes Pump and CGM Technology Pipeline DUBLIN & NEW YORK – Medtronic plc …See details»
How Private Capital Can Yield “Healthy” Returns - Blackstone
In 2018, the firm launched Blackstone Life Sciences (BXLS) through its acquisition of Clarus, a global life sciences investment firm, to invest directly in promising medicines and technologies.See details»
Five questions with Blackstone Life Sciences’ Nicholas Galakatos
Jul 27, 2020 And, as far as scale capital, this is the largest life sciences private fund raised to date. Clarus was acquired by Blackstone in 2018. What was the fundraising and now the …See details»
Blackstone Angles to Fill $150 Billion Life Sciences Funding Gap
1 day ago I sat down with Nick Galakatos, global head of life sciences at Blackstone, which has one of the largest dedicated pools of capital for funding clinical trials of vital medicines and …See details»
Blackstone Announces $4.6 Billion Final Close of Life Sciences
Jul 9, 2020 Blackstone Life Sciences is a private, global investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors.See details»
Blackstone Has Quietly Invested in Life Sciences for …
The pandemic put life sciences in the headlines, but Blackstone Group had been quietly building a multibillion-dollar stake in the business for the better part of a decade.See details»
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel ...
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences ("Blackstone") portfolio company Uniquity Bio, a clinical-stage drug …See details»
Blackstone Announces $4.6 Billion Final Close of Life Sciences Fund
Jul 9, 2020 Blackstone Life Sciences is a private, global investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. By …See details»
Blackstone continues biotech push with up to $250M cell therapy ...
Nov 8, 2021 Dive Brief: A life sciences fund managed by Blackstone will back Autolus Therapeutics with up to $250 million for development of a cell-based cancer treatment, the …See details»
Blackstone caps off private equity's largest-ever life sciences fund ...
Jul 10, 2020 Dive Brief: Blackstone has closed what it claims is the largest-ever private equity fund for life sciences investing, with $4.6 billion at its disposal as of Thursday. Before the …See details»
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel ...
May 15, 2024 With Blackstone Life Sciences supporting the company’s capital requirements, Uniquity Bio has a unique and sustainable business model that supports the parallel …See details»
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel ...
May 15, 2024 Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences (“Blackstone”) portfolio company Uniquity Bio, a clinical-stage drug development …See details»
Blackstone Life Sciences to invest up to $250 million in Autolus ...
Nov 8, 2021 As part of this $250 million transaction, Blackstone is committing to invest $150 million in product financing to support obe-cel development and commercialization, with $50 …See details»
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel ...
May 15, 2024 With Blackstone Life Sciences supporting the company’s capital requirements, Uniquity Bio has a unique and sustainable business model that supports the parallel …See details»
Life sciences M&A, divestments and restructuring - Deloitte
Oct 24, 2024 Over the past five years, M&A activity has rebounded strongly, driven in part by a step-up in investor activism. M&A has become a critical element in the corporate strategy of …See details»
Blackstone Life Sciences Expands Team of Biopharmaceutical, …
May 24, 2021 Cambridge, MA – Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former …See details»